Ultra-stable Iodized Oil-Chemo Embolization Seq Thermal Ablation in Early Liver Ca

A Clinical Study on the Use of Ultra-stable Homogeneous Iodized Oil - Chemotherapy Drug Formulation for Sequential Thermal Ablation After TACE Treatment for Unresectable/ Unwilling-to-surgery-resected Early-stage Liver Cancer

Background: In the treatment of liver cancer, TACE (transarterial chemoembolization) combined with ablation is commonly used. The chemotherapeutic drug iodized oil emulsion prepared by the ultra-stable homogeneous mixture formulation technology (SHIFT) is stable, efficient, and has low toxicity. However, its effectiveness has not been verified in the post-TACE thermal ablation treatment. Objective: To evaluate the efficacy and safety of the ultra-stable homogeneous iodized oil-chemotherapy drug formulation in the treatment of patients with unresectable/ unwilling to undergo surgical resection early hepatocellular carcinoma in the sequential TACE and thermal ablation therapy. Method: A prospective, single-arm, single-center, non-blinded study included 30 patients with stage Ia and some stage Ib hepatocellular carcinoma. They received TACE combined with thermal ablation using the ultra-stable homogeneous iodized oil-chemotherapy drug formulation, and then underwent enhanced MR to evaluate the complete response rate (CR) and other efficacy and safety indicators.

Study Overview

• Status: Active, not recruiting
• Conditions: Hepatocellular Carcinoma (HCC)
• Intervention / Treatment: Procedure: TACE combined with thermal ablation

Detailed Description

In the field of early liver cancer treatment where the cancer is not resectable or the patient refuses surgical resection for various reasons, the combined treatment approach of hepatic artery chemotherapy embolization (TACE) and ablation has become a commonly used and effective therapeutic method in clinical practice. The traditional combined treatment model mainly relies on traditional iodized oil embolic agents. However, this embolic agent has exposed many problems in practical application. On one hand, the drug stability is insufficient. After entering the human body, the mixed state of iodized oil and chemotherapy drugs is difficult to maintain for a long time, resulting in uneven drug release at the target site and the inability to fully exert the killing effect of the chemotherapy drugs. On the other hand, after embolization, hypoxia is prone to occur, reducing the oxygen supply to the local tumor tissue. This not only affects the sensitivity of tumor cells to chemotherapy drugs but also may activate some hypoxia adaptation mechanisms of tumor cells, promoting tumor progression and metastasis. These problems seriously restrict the further improvement of the efficacy of the existing combined treatment.

With the continuous development of medical technology, the ultra-stable homogeneous mixture formulation technology has emerged. The chemotherapy drug iodized oil emulsion prepared by this advanced technology has many significant advantages. It can maintain high stability, ensuring that the iodized oil and the chemotherapy drug are uniformly mixed in the body for a long time, allowing the drug to be precisely and continuously released into the tumor tissue, thereby improving the utilization rate of the drug and the therapeutic effect. At the same time, this emulsion also has the characteristics of high efficiency and low toxicity. It effectively kills tumor cells while causing less damage to normal tissues, reducing adverse reactions during the treatment process for patients and improving their quality of life. However, although the chemotherapy drug iodized oil emulsion prepared by the ultra-stable homogeneous mixture formulation technology has many theoretical advantages, it has not yet been verified for its effectiveness and safety in the specific scenario of thermal ablation treatment after TACE.

Based on this, this study aims to fill this gap and evaluate the efficacy and safety of the ultra-stable homogeneous iodized oil - chemotherapy drug formulation in patients with early hepatocellular carcinoma that is either unresectable or unwilling to undergo surgical resection, during the sequential TACE and thermal ablation treatment.

In the design of the research plan, a prospective, single-arm, single-center, non-blinded research model was adopted. It is planned to include 30 eligible patients with stage Ia and some stage Ib hepatocellular carcinoma. These patients will receive ultra-stable homogeneous iodized oil - chemotherapy drug TACE combined with thermal ablation therapy. After the treatment, comprehensive evaluations of efficacy indicators such as complete response rate (CR) will be conducted through advanced imaging examination methods such as enhanced MR. At the same time, adverse reactions that may occur during and after the treatment will be closely monitored to assess the safety of this treatment plan.

The general research process is as follows: Firstly, detailed informed consent is provided to patients who meet the inclusion criteria, ensuring that they fully understand the purpose, process, potential risks and benefits of the study. After the patients sign the informed consent form voluntarily, they are officially included in the study. Then, a comprehensive pre-treatment assessment is conducted for the patients, including physical condition, liver function, tumor size and location, etc., to accurately determine whether they have treatment indications and exclude patients with treatment contraindications, ensuring the safety and effectiveness of the treatment. After confirming that the patients are suitable for treatment, TACE therapy is performed for them. Through precise interventional operations, the stable homogeneous iodized oil - chemotherapy drug formulation is injected into the hepatic artery to achieve the dual purposes of embolizing tumor blood vessels and local chemotherapy. After the surgery, combined ablation therapy is carried out according to the specific conditions of the patients, further killing tumor cells. One to two months after the surgery, the patients are scheduled for a follow-up visit. Through enhanced MR and other examination methods, the treatment effect is preliminarily evaluated, observing changes in tumor size, shape, etc., and calculating efficacy indicators such as complete remission rate. At the same time, various adverse reactions that the patients have experienced during and after the treatment, such as fever, pain, abnormal liver function, etc., are recorded in detail, and the safety of the treatment plan is evaluated. Finally, the patients are followed up for one year, continuously monitoring the changes in their condition and survival status, providing data support for the long-term efficacy evaluation of the study.

• Study Type: Interventional
• Enrollment (Estimated): 30
• Phase: Not Applicable

Contacts and Locations

Study Locations

• China
  • Fujian
    • Fuzhou, Fujian, China, 350001
      • Department of Interventional Radiology, Fujian Medical University Union Hospital

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

• (1) The patient's gender is not restricted, and the age is between 18 and 60 years old, with an expected lifespan of ≥ 3 months; (2) Patients diagnosed with primary hepatocellular carcinoma confirmed by histological or cytological examination, or meeting the clinical diagnostic criteria of the "Primary Liver Cancer Diagnosis and Treatment Guidelines" (2024 Edition) issued by the National Health Commission (including chronic liver disease background, typical imaging features, and changes in AFP); (3) CNLC stage Ia and some Ib stage liver cancer (i.e., a single tumor with a diameter of ≤ 5 cm; or 2 to 3 tumors with the maximum diameter of ≤ 3 cm) (those who are not suitable for or unwilling to undergo surgical resection); (4) No vascular invasion of the portal vein, hepatic vein, etc.; (5) Liver function is Child-A grade or can be corrected after liver protection, nutritional fluid therapy, etc.; (6) Eastern Cooperative Oncology Group Status Score (ECOG PS) ≤ 2; (7) After treatment, the following indicators are achieved: white blood cell count ≥ 9.5×109/L and ≤ 3.0×109/L; platelet count ≥ 350×109/L and ≤ 50×109/L; prothrombin time (PT) does not exceed the upper limit of the normal control by 5 seconds; serum creatinine is less than 1.5 times the upper limit of the normal; alanine aminotransferase (ALT) and aspartate aminotransferase (AST) are less than 3 times the upper limit of the normal; (8) Clearly inform the patient of the possible advantages and disadvantages before and after the surgery, and the patient and his/her family voluntarily choose the treatment plan and sign the informed consent form.

Exclusion Criteria:

• (1) Patients who have received non-radical treatment for liver cancer (including external radiotherapy, molecular targeted drugs, immunotherapies, TAI/TAE/TACE treatments, etc.) and whose tumors are still alive, and patients who have experienced tumor recurrence after radical treatment for liver cancer (including surgical resection, ablation therapy) can be included in this study; (2) Portal vein or hepatic vein invasion; (3) Patients with already diagnosed malignant tumors in other parts; (4) Severe diseases of important organs such as heart, lungs, kidneys, and brain; (5) Complications of TACE contraindications: diffuse-type liver cancer or tumor volume accounting for 70% or more of the entire liver, refractory large amounts of ascites, high-flow arteriovenous shunt in the liver; total bilirubin > 51 umol/L and/or albumin < 28 g/L, which cannot be improved after symptomatic treatment; combined with active infection, especially inflammation of the biliary system; female patients who are pregnant or breastfeeding; (6) Patients allergic to iodine oil or iodine agents; (7) Patients and/or their families do not agree to participate in the clinical trial.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm

Intervention / Treatment

Experimental: Experimental arm; They received TACE combined with thermal ablation using the ultra-stable homogeneous iodized oil-chemotherapy drug formulation, and then underwent enhanced MR to evaluate the complete necrosis rate (CR) and other efficacy and safety indicators.

Procedure: TACE combined with thermal ablation; TACE therapy is performed. Through precise interventional operations, the stable homogeneous iodized oil - chemotherapy drug formulation is injected into the hepatic artery to achieve the dual purposes of embolizing tumor blood vessels and local chemotherapy. After TACE, combined ablation therapy is carried out according to the specific conditions of the patients, further killing tumor cells.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Complete remission rate	MRI/CT enhancement confirmed no residual activity.	"From enrollment to the end of treatment at 1 year"

Collaborators and Investigators

• Sponsor: Fujian Medical University Union Hospital

Study record dates

Study Major Dates

• Study Start (Actual): February 10, 2026
• Primary Completion (Estimated): August 31, 2027
• Study Completion (Estimated): November 30, 2027

Study Registration Dates

• First Submitted: March 20, 2026
• First Submitted That Met QC Criteria: March 20, 2026
• First Posted (Actual): March 25, 2026

Study Record Updates

• Last Update Posted (Actual): March 25, 2026
• Last Update Submitted That Met QC Criteria: March 20, 2026
• Last Verified: February 1, 2026

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Neoplasms by Site; Neoplasms; Neoplasms by Histologic Type; Digestive System Neoplasms; Digestive System Diseases; Liver Diseases; Neoplasms, Glandular and Epithelial; Adenocarcinoma; Liver Neoplasms; Carcinoma; Carcinoma, Hepatocellular
• Other Study ID Numbers: 2026KY009-01

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No